Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study

doi:10.4239/wjd.v12.i10.1789

科研成果详情

题名	Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study
作者	Luo, Shun-Kui 1; Hu, Wei-Hua 2; Lu, Zhan-Jin 1; Li, Chang 3; Fan, Ya-Meng 4; Chen, Qi-Jian 5; Chen, Zai-Shu 6; Ye, Jian-Fang 1; Chen, Shi-Yan 1; Tong, Jun-Lu 1; Wang, Ling-Ling 7; Mei, Jin 8,9; Lu, Hong-Yun 10
发表日期	2021-10-15
发表期刊	WORLD JOURNAL OF DIABETES 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Diabetes Coronavirus disease 2019 Mortality Risk factors Acarbose
其他关键词	INFLAMMATION
摘要	BACKGROUNDPrevious studies have shown that diabetes mellitus is a common comorbidity of coronavirus disease 2019 (COVID-19), but the effects of diabetes or anti-diabetic medication on the mortality of COVID-19 have not been well described.AIMTo investigate the outcome of different statuses (with or without comorbidity) and anti-diabetic medication use before admission of diabetic after COVID-19.METHODSIn this multicenter and retrospective study, we enrolled 1422 consecutive hospitalized patients from January 21, 2020, to March 25, 2020, at six hospitals in Hubei Province, China. The primary endpoint was in-hospital mortality. Epidemiological material, demographic information, clinical data, laboratory parameters, radiographic characteristics, treatment and outcome were extracted from electronic medical records using a standardized data collection form. Most of the laboratory data except fasting plasma glucose (FPG) were obtained in first hospitalization, and FPG was collected in the next day morning. Major clinical symptoms, vital signs at admission and comorbidities were collected. The treatment data included not only COVID-19 but also diabetes mellitus. The duration from the onset of symptoms to admission, illness severity, intensive care unit (ICU) admission, and length of hospital stay were also recorded. All data were checked by a team of sophisticated physicians.RESULTSPatients with diabetes were 10 years older than non-diabetic patients [(39 - 64) vs (56 - 70), P < 0.001] and had a higher prevalence of comorbidities such as hypertension (55.5% vs 21.4%, P < 0.001), coronary heart disease (CHD) (9.9% vs 3.5%, P < 0.001), cerebrovascular disease (CVD) (3% vs 2.2%, P < 0.001), and chronic kidney disease (CKD) (4.7% vs 1.5%, P = 0.007). Mortality (13.6% vs 7.2%, P = 0.003) was more prevalent among the diabetes group. Further analysis revealed that patients with diabetes who took acarbose had a lower mortality rate (2.2% vs 26.1, P < 0.01). Multivariable Cox regression showed that male sex [hazard ratio (HR) 2.59 (1.68 - 3.99), P < 0.001], hypertension [HR 1.75 (1.18 - 2.60), P = 0.006), CKD [HR 4.55 (2.52-8.20), P < 0.001], CVD [HR 2.35 (1.27 - 4.33), P = 0.006], and age were risk factors for the COVID-19 mortality. Higher HRs were noted in those aged & GE; 65 (HR 11.8 [4.6 - 30.2], P < 0.001) vs 50-64 years (HR 5.86 [2.27 - 15.12], P < 0.001). The survival curve revealed that, compared with the diabetes only group, the mortality was increased in the diabetes with comorbidities group (P = 0.009) but was not significantly different from the non-comorbidity group (P = 0.59).CONCLUSIONPatients with diabetes had worse outcomes when suffering from COVID-19; however, the outcome was not associated with diabetes itself but with comorbidities. Furthermore, acarbose could reduce the mortality in diabetic.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670815]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010124, 2021A1515010695]; Special Fund for Innovation Strategy of Science and Technology plan of Guangdong Province [2019A030317011]
出版者	BAISHIDENG PUBLISHING GROUP INC
出版地	PLEASANTON
ISSN	1948-9358
EISSN	1948-9358
卷号	12 期号:10 页码:1789-1808
DOI	10.4239/wjd.v12.i10.1789
页数	20
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000719348700013
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	34754379
通讯作者地址	[Lu, Hong-Yun]Jinan Univ, Dept Endocrinol & Metab, Zhuhai Hosp, 79 Kangning Rd, Zhuhai 519000, Guangdong, Peoples R China.
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20372
专题	基础医学院（机能实验教学中心）_形态学系_人体解剖学
通讯作者	Lu, Hong-Yun
作者单位	1.Sun Yat Sen Univ, Dept Endocrinol & Metab, Affiliated Hosp 5, Zhuhai 519000, Guangdong, Peoples R China; 2.Yangtze Univ, Hosp Jingzhou 1, Clin Med Coll, Dept Resp Med, Jingzhou 434000, Hubei, Peoples R China; 3.Jianghan Univ, Dept Cardiol, Hubei 3 Peoples Hosp, Wuhan 430033, Hubei, Peoples R China; 4.Wuhan Univ, Sch Hlth Sci, Wuhan 430071, Hubei, Peoples R China; 5.Fifth Hosp Wuhan, Dept Emergency Med, Wuhan 430050, Hubei, Peoples R China; 6.Peoples Hosp Jiayu Cty, Jiayu 437200, Hubei, Peoples R China; 7.Sun Yat Sen Univ, Dept Gerontol, Affiliated Hosp 5, Zhuhai 519000, Guangdong, Peoples R China; 8.Wenzhou Med Univ, Anat Dept, Wenzhou 325035, Zhejiang, Peoples R China; 9.Zhejiang Univ, Cent Lab, Ningbo Hosp 1, Ningbo 315010, Zhejiang, Peoples R China; 10.Jinan Univ, Dept Endocrinol & Metab, Zhuhai Hosp, 79 Kangning Rd, Zhuhai 519000, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Luo, Shun-Kui,Hu, Wei-Hua,Lu, Zhan-Jin,et al. Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study[J]. WORLD JOURNAL OF DIABETES,2021,12(10):1789-1808.
APA	Luo, Shun-Kui., Hu, Wei-Hua., Lu, Zhan-Jin., Li, Chang., Fan, Ya-Meng., ... & Lu, Hong-Yun. (2021). Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study. WORLD JOURNAL OF DIABETES, 12(10), 1789-1808.
MLA	Luo, Shun-Kui,et al."Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study".WORLD JOURNAL OF DIABETES 12.10(2021):1789-1808.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
WJDE202110013.caj（970KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览下载